TrialCardiovascular diabetology2015

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.

Michael Roden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.